Regeneron reports 84-week Pasatru data: stock pre-market at EUR 673.30
Published on 10/14/2026 at 07:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTrial findings and trading outlook
- Regeneron disclosed 84-week Pasatru trial findings on October 12, 2026.
- Regeneron stock trades pre-market at EUR 673.30 at 7:53 a.m. CEST at Lang & Schwarz on October 14, 2026.
- The OPTIMA extension included 63 adult participants and 58 completed the double-blind extension phase.
Regeneron Pharmaceuticals, Inc. reported positive 84-week results from the Phase 3 OPTIMA trial for Pasatru on October 12, 2026, according to the company’s release. Regeneron stock trades pre-market at EUR 673.30 at 7:53 a.m. CEST at Lang & Schwarz on October 14, 2026.
Pre-market price
Regeneron’s bid was EUR 670.00 and its ask was EUR 676.60 at the same time. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Regeneron stock.
Pasatru trial findings
The OPTIMA trial enrolled 63 adults with fibrodysplasia ossificans progressiva. After the initial 56-week period, 58 participants completed the double-blind extension phase to at least 84 weeks, the company release said.
From week 56 to week 84, no new heterotopic ossification lesions were observed for Pasatru compared with 9 for placebo in the computed tomography assessment. The release said one new lesion previously detected at week 56 for the 3 mg/kg Pasatru dose was no longer detectable at week 84.
What matters today
The latest company-specific development is dated October 12, 2026 and covers 84-week OPTIMA findings. The trial’s 63 adult participants were assigned to Pasatru 10 mg/kg, Pasatru 3 mg/kg or placebo every four weeks during the 56-week treatment period. The extension included 58 participants and continued to at least 84 weeks.
Market context: Market report S&P 500.
